OncoMatch/Clinical Trials/NCT05914662
Zanubrutinib Plus BR in Newly Diagnosed Symptomatic WM
Is NCT05914662 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies Zanubrutinib, Bendamustine and Rituximab for waldenstrom macroglobulinemia.
Treatment: Zanubrutinib, Bendamustine and Rituximab — This study aims to evaluate the long-term efficacy of BTK inhibitor Zanubrutinib combined bendamustine and rituximab (ZBR) for time-limited treatment of Waldenstrom macroglobulinemia, The combination therapy is expected to improve the remission depth, prolong the remission time, and improve the progression-free survival and overall survival of newly diagnosed WM patients. On the one hand, the patients have to bear a long-term economic burden, which is often difficult for some patients to adhere to for a long time. On the other hand, in the course of long-term treatment of BTKi, drug resistance and intolerable side effects are prone to occur. At the same time, it can prevent the disease rebound after the withdrawal of BTKi, so as to achieve the phased withdrawal of WM
Check if I qualifyExtracted eligibility criteria
Cancer type
Non-Hodgkin Lymphoma
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Cannot have received: BTK inhibitor
No combined chemotherapy with BTKi
Cannot have received: BR
No combined chemotherapy with BR
Cannot have received: RCD
No combined chemotherapy with RCD
Cannot have received: VRD
No combined chemotherapy with VRD
Cannot have received: CHOP
No combined chemotherapy with CHOP
Cannot have received: COP
No combined chemotherapy with COP
Cannot have received: fludarabine-containing regimen (fludarabine)
No treatment regimen containing fludarabine
Cannot have received: chlorambucil (chlorambucil)
Exception: less than 4 weeks (alone or in combination with adrenal glucocorticoids), and did not reach the treatment response (MR)
Chlorambucil or cyclophosphamide for less than 4 weeks (alone or in combination with adrenal glucocorticoids); The above treatment did not reach the treatment response (MR)
Cannot have received: cyclophosphamide (cyclophosphamide)
Exception: less than 4 weeks (alone or in combination with adrenal glucocorticoids), and did not reach the treatment response (MR)
Chlorambucil or cyclophosphamide for less than 4 weeks (alone or in combination with adrenal glucocorticoids); The above treatment did not reach the treatment response (MR)
Lab requirements
Blood counts
neutrophils ≥ 0.75×10^9/l; platelets ≥ 50×10^9/l
Kidney function
creatinine clearance rate ≥ 30ml/min
Liver function
total bilirubin ≤ 2.5 times upper limit; alanine aminotransferase/aspartate aminotransferase ≤3 times upper limit
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify